Literature DB >> 2522404

Overview of recent clinical pharmacokinetic studies with acitretin (Ro 10-1670, etretin).

C J Brindley1.   

Abstract

Following oral administration of acitretin with food, peak plasma concentrations of unchanged drug (Ro 10-1670) are reached within 4 h. The mean absolute bioavailability of acitretin is 59% with high interpatient variability consistent with that of etretinate. Taking acitretin with food results in an increased and more consistent bioavailability. The drug appears to be extensively distributed throughout the body without unexpected accumulation and the elimination half-life is approximately 50 h. Acitretin has a profound pharmacokinetic advantage over etretinate because it is eliminated more rapidly from the body; etretinate is sequestered into fatty tissue due to its greater lipophilicity creating a deep compartment from which it is only slowly released. Acitretin is eliminated entirely by the metabolism and the resultant metabolites are excreted via the kidney and bile.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2522404     DOI: 10.1159/000248397

Source DB:  PubMed          Journal:  Dermatologica        ISSN: 0011-9075


  4 in total

Review 1.  Pharmacokinetics and therapeutic efficacy of retinoids in skin diseases.

Authors:  F G Larsen; F Nielsen-Kudsk; P Jakobsen; K Weismann; K Kragballe
Journal:  Clin Pharmacokinet       Date:  1992-07       Impact factor: 6.447

Review 2.  Current use and future potential role of retinoids in dermatology.

Authors:  C E Orfanos; C C Zouboulis; B Almond-Roesler; C C Geilen
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

3.  The distribution of cis- and trans-acitretin in human epidermis.

Authors:  E Meyer; W Lambert; A De Leenheer; J De Bersaques; A Kint
Journal:  Br J Clin Pharmacol       Date:  1992-02       Impact factor: 4.335

4.  Acitretin : A Review of its Pharmacology and Therapeutic Use.

Authors:  Tania Pilkington; Rex N Brogden
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.